This article first appeared on GuruFocus .
Release Date: February 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Ambea AB ( FRA:6MA ) reported a 15% increase in net sales for Q4 2025, driven by acquisitions and solid organic growth.
-
The company has an industry-leading pipeline with almost 1,700 care places, supporting long-term growth potential.
-
Ambea AB ( FRA:6MA ) achieved an adjusted EBITA of 347 million SEK with an EBITDA margin of 8.3%.
-
The company continues to invest in leadership and operational improvements, launching new leadership programs to enhance execution and strategic capabilities.
-
Ambea AB ( FRA:6MA ) maintains a strong financial position with a leverage ratio of 2.3 times net debt to EBITDA, well below the target of 3.25 times.
Negative Points
-
The adjusted EBITDA margin decreased by 1.2 percentage points from the previous year's Q4, reflecting increased investments and costs.
-
Standi, the Norwegian business area, experienced a weaker quarter with fluctuating occupancy impacting profitability.
-
The company faced currency headwinds, particularly affecting the performance of Alti and Standi.
-
There were significant investments in IT infrastructure and cybersecurity, which, while necessary, impacted short-term financial performance.
-
The integration of recent acquisitions, such as Validia, incurred additional costs, affecting the overall margin.
Q & A Highlights
-
Warning! GuruFocus has detected 8 Warning Signs with FRA:6MA.
-
Is FRA:6MA fairly valued? Test your thesis with our free DCF calculator.
Q: Could you provide guidance on the cost effects of your investments in operational structure, IT, and training? A: Mark Jensen, CEO: While I can't provide specific guidance on cost effects, our investments are driven by our strong pipeline for organic growth and our entry into Finland. These investments ensure quality growth and attractive workplaces. Importantly, these will not impact our financial targets, and we remain committed to delivering a 9.5% EBITA margin.
Q: With Valdog entering a growth phase, how should we view its margin development over the coming years? A: Benno Liasson, CFO: In the short term, margins may be impacted by new openings, but over time, as these nursing homes ramp up, margins will strengthen. We have several openings planned for 2027 and 2028, which will affect margins initially but improve them as they mature.
Q: Can we expect cost efficiencies in Standi as you adjust to demand? A: Mark Jensen, CEO: Yes, we are working on operational improvements as we adjust capacity to demand. We aim to create a more effective structure with larger care homes, which will lead to operational efficiencies.
Q: Will you continue with bolt-on acquisitions at a similar pace in 2026, and where is your strongest pipeline? A: Mark Jensen, CEO: We will remain active in the M&A market, focusing on quality acquisitions across all markets. The strongest pipeline is in the new theater segment and for Validia in Finland, but we are exploring opportunities in all countries and business areas.
Q: Could you break down the 20 million integration costs for Validia? A: Benno Liasson, CFO: The integration costs include IT and contract exchanges. We've completed the integration faster than planned, which is why the costs are slightly higher. Validia is now ready for new acquisitions without further integration dependency.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
